Alkermes Plc Hits New 52-Week High of $48.30, Up 98.72%

Alkermes Plc has reached a significant milestone by hitting a new 52-week high of USD 48.30 on June 23, 2026. This achievement highlights the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it operates as a small-cap entity with a market capitalization of USD 5,008 million. Over the past year, Alkermes has demonstrated impressive growth, with a remarkable 98.72% increase in its stock price, significantly outperforming the S&P 500, which recorded a 22.24% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 21.00, indicating a solid valuation relative to its earnings. Alkermes maintains a return on equity of 13.28%, showcasing its ability to generate profits from shareholders' equity. Additionally, the company has a price-to-book ratio of 2.75, reflecting its market valuation compared to its book value. With no dividend yield and a debt-to-equity ratio of -0.72, Alkermes continues to navigate the competitive landscape of the pharmaceutical industry effectively.